Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, today announced that its NDA for a 6-month formulation of TRELSTAR (triptorelin pamoate), a luteinizing hormone releasing hormone (LHRH) agonist, has been accepted for filing by the U.S. FDA.
The details can be read here.
No comments:
Post a Comment